Arzerra Disappoints in NHL, Putting Genmab on Shaky Ground
This article was originally published in The Pink Sheet Daily
Executive Summary
Ofatumumab failed to live up to expectations in a Phase III NHL trial, meaning no milestone payment from partner GlaxoSmithKline and revised 2009 guidance.